Daniel Egnacheski
Psychiatric/Mental Health · Youngstown, OHNPI 1124731005
Payments from drug & device makers
Across 314 payments — averaging $18.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Teva Pharmaceuticals USA, Inc.$904
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$583
- Johnson & Johnson$494
- Lundbeck LLC$447
- Otsuka America Pharmaceutical, Inc.$416
- plus $2K from 13 others
What the payments were for
- Food & beverage$5,46796%
- Education$2234%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 57 | $1,243 |
| Teva Pharmaceuticals USA, Inc. | 78 | $904 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 32 | $583 |
| Johnson & Johnson | 19 | $494 |
| Lundbeck LLC | 28 | $447 |
| Otsuka America Pharmaceutical, Inc. | 19 | $416 |
| Alkermes, Inc. | 14 | $326 |
| Almatica Pharma LLC | 12 | $245 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $185 |
| Corium, LLC | 8 | $155 |
| E.r. Squibb & Sons, L.L.C. | 7 | $152 |
| Neurocrine Biosciences, Inc. | 9 | $135 |
| Axsome Therapeutics, Inc. | 5 | $88 |
| Supernus Pharmaceuticals, Inc. | 5 | $79 |
| Tris Pharma Inc | 5 | $78 |
| Vanda Pharmaceuticals Inc. | 2 | $64 |
| Ironshore Pharmaceuticals Inc. | 2 | $41 |
| Idorsia Pharmaceuticals US Inc | 2 | $32 |
| Tempus AI, Inc | 1 | $22 |
How this compares
$5,690 in reported general payments places this provider in the 90th percentile of 1,808 psychiatric/mental health providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 29 | $247,772 |
| IngrezzaValbenazine Tosylate | 21 | $174,217 |
| AristadaAripiprazole Lauroxil | 40 | $131,338 |
| AustedoDeutetrabenazine | 12 | $111,797 |
| RexultiBrexpiprazole | 35 | $69,371 |
| Aripiprazole | 274 | $46,847 |
| Abilify MaintenaAripiprazole | 15 | $46,293 |
| PerserisRisperidone | 13 | $41,581 |
| TrintellixVortioxetine Hydrobromide | 61 | $38,153 |
| NuedextaDextromethorphan Hbr/Quinidine | 21 | $32,406 |
| Invega SustennaPaliperidone Palmitate | 13 | $31,805 |
| FanaptIloperidone | 13 | $28,174 |
| Paliperidone ErPaliperidone | 57 | $25,341 |
| VraylarCariprazine Hcl | 19 | $24,939 |
| Divalproex Sodium | 211 | $12,678 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $904 | $359,56941 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $135 | $174,21721 claims |
| Alkermes, Inc.Aristada | $326 | $131,33840 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $416 | $115,66450 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $185 | $38,15361 claims |
| Johnson & JohnsonInvega Sustenna | $494 | $31,80513 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $64 | $28,17413 claims |
| AbbVieVraylar | $1,243 | $24,93919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,808 psychiatric/mental health providers in Ohio.
Other psychiatric/mental health in Youngstown
- Robert ParsonsYoungstown$119K
- Noah HochendonerYoungstown$34K
- Crystal TravisJackson$333K
- Kristina RoweIronton$253K
- Patricia SparksPortsmouth$210K
- Mary HallWarren$195K
- Kassandra KornbauCanfield$170K
- Terri PopovitzCincinnati$161K
- Steven MatesDayton$121K
- Chriscia BaneChillicothe$115K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.